Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 5899.084 | 0.8978 | 0.8156 | 1.1144 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 5899.084 | 0.5505 | 0.1706 | 1.1144 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 5900.085 | 0.9326 | 0.9478 | 2.6391 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 5900.085 | 0.9624 | 0.9712 | 2.6391 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 5900.085 | 0.9635 | 0.9720 | 2.6391 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 5900.085 | 0.9887 | 0.9914 | 2.6391 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 5900.085 | 1.0420 | 1.0315 | 2.6391 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 5900.085 | 1.0192 | 1.0144 | 2.6391 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 5900.085 | 0.9574 | 0.9673 | 2.6391 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 5900.085 | 0.4846 | 0.5199 | 2.6391 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 5900.085 | 1.2147 | 1.1530 | 2.6391 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 5901.084 | 0.9845 | 0.9821 | 1.7402 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 5901.084 | 1.0248 | 1.0283 | 1.7402 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 5901.084 | 0.9581 | 0.9514 | 1.7402 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 5901.084 | 0.9994 | 0.9993 | 1.7402 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 5901.084 | 1.0210 | 1.0240 | 1.7402 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 5901.084 | 1.0228 | 1.0260 | 1.7402 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 5901.084 | 0.9325 | 0.9212 | 1.7402 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 5901.084 | 0.7061 | 0.6375 | 1.7402 | |
| AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 5901.084 | 0.4752 | 0.3042 | 1.7402 | |
| BT-20 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 5902.084 | 0.9000 | 0.8502 | 1.3532 | |
| BT-20 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 5902.084 | 1.0179 | 1.0264 | 1.3532 | |
| BT-20 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 5902.084 | 0.9450 | 0.9181 | 1.3532 | |
| BT-20 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 5902.084 | 0.9595 | 0.9399 | 1.3532 | |
| BT-20 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 5902.084 | 1.2331 | 1.3349 | 1.3532 |